TuHURA Biosciences wins new US patent covering VISTA inhibitor TBS-2025

HURA•2026-10-13

TuHURA Biosciences received a US patent covering its VISTA-inhibiting antibody TBS-2025, with a term running to Feb. 18, 2042, before any adjustments or extensions.

1. Patent coverage

The patent covers TBS-2025 and antibody fragments, modifications and bispecific or multi-specific formats across human antibody classes. Claims include monotherapy and combination regimens, including with PD-1 inhibitors, and methods of use in oncology, autoimmune disease and infection.

TuHURA Biosciences wins new US patent covering VISTA inhibitor TBS-2025

1. Patent coverage

Related News

Clean Harbors issues 2026 sustainability report, cites net climate benefit factor above 2x 2025 operational GHG emissions

BioNTech's mRNA cancer therapy misses first goal in head and neck trial

Biodexa enrolls 100th patient in Serenta Phase 3 eRapa trial

Yiren Digital CEO Ning Tang faces criminal compulsory measures in affiliate probe, police notice says

Roze AI signs new contracts worth about $14.8 million in South Korea